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Abstract
Background: Hemostasis is the dynamic equilibrium between coagulation and fibrinolysis. During pregnancy, the
balance shifts toward a hypercoagulative state; however placental abruption and abnormal placentations may lead
to rapidly evolving coagulopathy characterized by the increased activation of procoagulant pathways. These
processes can result in hypofibrinogenemia, with fibrinogen levels dropping to 2 g/L or less and an associated
increased risk of post-partum hemorrhage.
The aim of the present study was to evaluate the concordance between two methods of functional fibrinogen
measurement: the Thromboelastography (TEG) method (also known as FLEV) vs. the Clauss method. Three patient
groups were considered: healthy volunteers; non-pathological pregnant patients; and pregnant patients who went
on to develop postpartum hemorrhage.
Methods: A prospective observational study. Inclusion criteria were: healthy volunteer women of childbearing age,
non-pathological pregnant women at term, and pregnant hemorrhagic patients subjected to elective or urgent
caesarean section (CS), with blood loss exceeding 1000 mL. Exclusion criteria were age < 18 years, a history of
coagulopathy, and treatment with contraceptives, anticoagulants, or antiplatelet agents.
Results: Bland-Altman plots showed a significant overestimation with the FLEV method in all three patient groups:
bias was − 133.36 mg/dL for healthy volunteers (95% IC: − 257.84; − 8.88. Critical difference: 124.48); − 56.30 mg/dL
for healthy pregnant patients (95% IC: − 225.53; 112.93. Critical difference: 169.23); and − 159.05 mg/dL for
hemorrhagic pregnant patients (95% IC: − 333.24; 15.148. Critical difference: 174.19). Regression analyses detected a
linear correlation between FLEV and Clauss for healthy volunteers, healthy pregnant patients, and hemorrhagic
pregnant patients (R2 0.27, p value = 0.002; R2 0.31, p value = 0.001; R2 0.35, p value = 0.001, respectively). ANOVA
revealed a statistically significant difference in fibrinogen concentration between all three patients groups when
assayed using the Clauss method (p value < 0.001 for all the comparisons), but no statistically significant difference
between the two patients groups of pregnant women when using the FLEV method.
Conclusions: The FLEV method does not provide a valid alternative to the Clauss method due to the problem of
fibrinogen overestimation, and for this reason it should not be recommended for the evaluation of patients with an
increased risk of hypofibrinogenemia.
Keywords: Thromboelastography, Post-partum hemorrhage, Coagulopathy, Fibrinogen
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: sd7782.do@gmail.com
1Anesthesiology and Intensive Care Medicine, Department of Medicine,
University of Udine, P.le S. Maria della Misericordia 15, 33100 Udine, Italy
Full list of author information is available at the end of the article
Spasiano et al. BMC Anesthesiology           (2019) 19:90 
https://doi.org/10.1186/s12871-019-0769-8
Background
Hemostasis is the dynamic equilibrium between coagula-
tion and fibrinolysis. During pregnancy, the balance
shifts to a hypercoagulative state that becomes more
pronounced toward the end of the third trimester,
returning to normality approximately 4 to 5 weeks after
delivery. Hypercoagulability results from an increase in
plasma concentrations of coagulation factors VII, VIII,
X, XII, von Willebrand factor (vWF), and fibrinogen
(which can reach 6 g/L by the end of pregnancy) [1].
Gestational thrombocytopenia may also occur during
the third trimester with platelet counts dropping by ap-
proximately 10% with respect to baseline [2]. Fibrinolysis
is also markedly depressed during a normal pregnancy
[2]. It is important to highlight that the coagulation
changes occurring during postpartum hemorrhage
(PPH) differ from those of polytraumatized or postsurgi-
cal patients because of the underlying cause of obstetric
bleeding [3].
Uterine atony, genital tract trauma, and surgical
trauma are not always associated with development of
coagulopathy, although they may cause significant blood
loss. However, uncontrolled bleeding in this context may
evolve into a late coagulopathy [4–7]. In contrast, pla-
cental abruption (even with minimal blood loss) and ab-
normal placentations may be associated with rapidly
evolving coagulopathy characterized by the consumption
of coagulation factors. Placental abruption and amniotic
fluid embolism are the main causes of the onset of dis-
seminated intravascular coagulopathy (DIC) [1, 8].
During PPH, fibrinogen is of fundamental importance,
and a blood level of fibrinogen less than 2 g/L (200 mg/
dL) is a positive predictive value for severe PPH and the
need for angiographic invasive procedures [9, 10], higher
blood and plasma transfusion, and a longer stay in the
intensive care unit [11–15]. A reliable and rapid method
for determining fibrinogenemia is therefore essential in
order to be able to intervene quickly. Functional fibrino-
gen (FLEV) assessment by TEG [16] and the gold stand-
ard laboratory Clauss method are the two most
widespread methods for assaying circulating fibrinogen
levels.
FLEV, as a point-of-care (POC) test, has the advantage
of providing results more rapidly, however, concerns
have been raised about the accuracy of FLEV measure-
ment in patients with a hemorrhage in progress, al-
though the obstetric context has never been specifically
analyzed until now. Several studies have reported a good
correlation between functional fibrinogen measured by
TEG (FLEV) and laboratory- diagnosed fibrinogenemia
as assessed using the Clauss method, whereas other
studies have shown TEG to overestimate actual levels
[17–19]. Specifically, TEG estimates the functional fi-
brinogen level (FLEV), by extrapolation from the MA
(maximal amplitude) fibrinogen value. The MA value of
a platelet-free plasma clot is proportionate to the func-
tional fibrinogen concentration. Analytical software is
able to calculate the functional fibrinogen level (MAFF
or FLEV) by transformation of the MA value. The gold
standard method, however, is the Clauss assay that needs
to be carried out in a clinical laboratory. For its execu-
tion, a standard curve is created by determining the
thrombin time for different plasma dilutions with a
known fibrinogen concentration. In brief, a citrated
whole blood sample is taken from a patient, centrifuged,
and the plasma portion stored. The plasma is then di-
luted 1:10 and the thrombin time calculated. The mea-
sured thrombin time is then placed on the standard
curve and the fibrinogen concentration extrapolated.
The aim of the present study was to evaluate the con-
cordance between the two most widely used methods of
fibrinogen measurement – TEG and the Clauss method
– in i) healthy volunteers, ii) non pathological pregnant
patients, and iii) pregnant patients who developed PPH.
Methods
Materials and methods
This prospective observational study was conducted at
the University Hospital of Udine and approved by the
local Ethics Committee (prot. N. 17534). Inclusion cri-
teria were: healthy volunteer women of childbearing age
(“healthy volunteers”), non-pathological pregnant
women at term (“non-pathological pregnant patients”)
and pregnant hemorrhagic patients (“hemorrhagic preg-
nant patients”) subjected to elective or urgent caesarean
section (CS), with blood loss exceeding 1000 mL. Exclu-
sion criteria were age < 18 years, a history of coagulopa-
thy, and treatment with contraceptives, anticoagulants,
or antiplatelet agents.
For each patient, the following preoperative data were
collected: age, gestational age, and reason for cesarean
section. The intraoperative data collected consisted of
the following blood levels/values: hemoglobin (Hb),
hematocrit (HCT), red blood cells, platelets, PT, aPTT,
INR, D-Dimer, Antithrombin (AT), Clauss fibrinogen,
thrombolelastographic parameters (R, K, Angle ɑ, MA,
CI, Ly30), FLEV, and the volume of blood loss. If blood
loss exceeded 1000 mL, the patients were designated to
the “hemorrhagic pregnant patients” group. For healthy
volunteers, we recorded hemoglobin (Hb), hematocrit
(HCT), red blood cells, platelets, PT, aPTT, INR, D-
Dimer, Antithrombin (AT), Clauss fibrinogen, TEG pa-
rameters, and FLEV. In the operating room, all patients
were monitored for heart rate (HR), noninvasive blood
pressure (NIBP), peripheral arterial saturation (SpO2),
and EtCO2 with in-out gas analysis. Regional or general
anesthesia was performed according to internal
protocols. Blood samples for thromboelastographic
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examination were collected into a blood tube containing
citrate (0.13M) and analyzed using a TEG® 5000 Throm-
belastograph® Hemostasis Analyzer (Haemoscope Cor-
poration, Niles, IL, USA). This point-of-care instrument
was subjected to a daily quality control protocol (e-test,
bubble test and level 1 and 2 controls), and the manu-
facturer’s instructions were always followed. The staff
performing the tests had undergone comprehensive
training. In our Institute, staff are also subjected to peri-
odic evaluations to check their ability to perform the
tests. The TEG FLEV calculation was performed by the
TEG® system’s internal software (Haemoscope Corpor-
ation, Niles, IL, USA). A blood volume equal to 360 μL
was taken from the sampling tube and placed, using a
special pipette, in a preheated cuvette at 37 °C contain-
ing 20 μL calcium for TEG parameter analysis.
To perform the functional fibrinogen (FF) assay
(Clauss method), 0.5 mL of citrated blood was added to
the designated FF vial containing abciximab (a monoclo-
nal antibody that inhibits platelet aggregation), tissue
factor (a glycoprotein necessary for the formation of
thrombin), sodium azide (the sodium salt of hydrogen
azide – a preservative of biological fluids), and tris buffer
(buffer salt solution for pH management) and gently
mixed. A 340 μL aliquot was transferred from the FF vial
to a 37 °C preheated TEG cuvette preloaded with 20 μL
0.2M CaCl2. The samples were analyzed within 30min
of sampling, and the thromboelastographic trace was
generated and analyzed within 90min. The samples for
both thromboelastography and the Clauss assay were
collected simultaneously. Blood samples for
hemoglobin, hematocrit, red blood cell and platelets
evaluation were collected into tubes containing ethyl-
enediaminetetraacetic acid (EDTA); samples for hemo-
gens and fibrinogen analysis were collected into tubes
containing citrate 0.13M.
Statistical analysis
Considering a linear correlation of 0.5 (for an alpha
value of 5% and a statistical power of 90%), we calcu-
lated a minimal sample size of 32 patients for each
group. Descriptive statistics were calculated for the main
study variables. For the comparison of qualitative vari-
ables, we considered frequencies and percentages; for
quantitative variables, we considered means and stand-
ard deviations (SD). The Bland-Altman plot was used to
evaluate the level of agreement between the results of
the Clauss method and FLEV for each group [20]. The
correlation between the two measures of fibrinogen and
between platelets, hemoglobin, and the TEG parameters
(maximum amplitude [MA] and the alpha angle) was
studied using the Spearman correlation coefficient calcu-
lated for each group. The relationship between the two
methods of fibrinogen determination was analyzed for
each group by linear regression analysis. A p value ≤0.05
was considered significant. A multiple comparison be-
tween groups for both methods of fibrinogen determin-
ation was made using ANOVA. A multiplicity
adjustment was obtained using the Westfall test. All stat-
istical analyses were performed using R-Cran ver. 3.4.2
language and environment for statistical computing (R
Core Team; R Foundation for Statistical Computing,
Vienna, Austria, http://www.R-project.org).
Results
Between October 2016 and June 2017, 103 participants
were enrolled onto the study. Two patients were ex-
cluded for a distorted TEG trace due to technical prob-
lems and a further 3 due to delays in the samples
arriving in the clinical laboratory. The final number of
participants was 98: 32 healthy volunteers, 34 pregnant
patients at full-term, and 32 pregnant patients with
hemorrhage. No participants were found to have coagu-
lation abnormalities or were being treated with anti-
platelet or anticoagulant therapies. The characteristics of
the studied population are shown in Table 1. The stud-
ied variables are shown in Table 2.
The Bland-Altman plots showed fairly good correl-
ation between the two measures, but the FLEV measure-
ments consistently were consistently higher than those
obtained quantitatively by the Clauss method: bias was
− 133.36 mg/dL for healthy volunteers (95% IC: − 257.84;
− 8.88. Critical difference: 124.48) (Fig. 1a); − 56.30 mg/
dL for healthy pregnant patients (95% IC: − 225.53;
112.93. Critical difference: 169.23) (Fig. 1b); and −
159.05 mg/dL for hemorrhagic pregnant patients
(95%IC: − 333.24; 15.148. Critical difference: 174.19) Fig.
1c. In 3 of the 32 cases of pregnant women with post-
partum hemorrhage, clinical treatment of fibrinogenemia
was only initiated once the laboratory results had been
obtained that revealed the overestimation of FLEV by
TEG (that had provided an incorrect estimate above
250 mg/dL). The Spearman correlation between FLEV
and Clauss was 0.39 (p = 0.027) in healthy volunteers,
0.54 (p = 0.001) in the pregnant term patients, and 0.57
(p = 0.001) in the hemorrhagic pregnant patients. Re-
gression analyses detected a linear correlation between
FLEV and Clauss for healthy volunteers, healthy preg-
nant patients, and hemorrhagic pregnant patients (R2
0.27, p value = 0.002; R2 0.31, p value = 0.001; R2 0.35, p
value = 0.001, respectively). ANOVA analysis demon-
strated statistically significant differences in fibrinogen
assayed using the Clauss method between the three
groups of patients (p value < 0.001 for all the compari-
sons) (Fig. 2b). On the contrary, no statistically signifi-
cant difference was present between the two groups of
pregnant patients when the FLEV method was used (p
value < 0.001 for the comparisons between healthy
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volunteers and pregnant patients; p value = 0.186 for the
comparison between healthy and hemorrhagic pregnant
patients) (Fig. 2a).
Discussion
The main finding of the current work is that fibrinogen
estimation by FLEV in pregnant term women and
hemorrhagic pregnant patients does not correlate closely
enough with the levels obtained via the quantitative
Clauss assay.
The FLEV methodology was developed in order to ob-
tain precise measures of fibrinogen as fast as possible,
i.e., at the bedside. In particular, its use would bring par-
ticular benefit to patients with fibrinogen levels lower
than 250mg/dL, so to permit its rapid correction in
cases of acute bleeding. As a matter of fact, fibrinogen
measurements have been incorporated into the latest
transfusion algorithms for patients undergoing cardiac
surgery, polytrauma patients, and the management of
pregnant patients developing postpartum hemorrhage,
for whom early correction is essential for levels lower
than 250 mg/dL. Indeed, fibrinogenemia less than 250
mg/dL has been identified as an early marker of pro-
gression to larger volume and more prolonged
hemorrhage, higher rates of red blood cell and plasma
transfusion, invasive angiographic procedures, and
prolonged hospital stays.
The management protocol of massive hemorrhage
bleeding highlights the importance of fibrinogenemia
correction, which, in addition to laboratory tests,
recommends the performance of viscoelastic methods,
i.e., rotational thromboelastometry (ROTEM) or throm-
boelastography (TEG) when available. TEG seems to be
a promising application in that it is a rapid test that does
not require highly specialized personnel and results are
available in only 15–20min. By contrast, the time re-
quired to complete a Clauss assay is two- or even three-
fold that for TEG, requiring 40 to 60min.
Regarding the two techniques, ROTEM has showed
better predictive accuracy than TEG in cardiac surgery
and trauma patients [19, 21, 22]. Whereas in pregnant
women and liver transplantation patients, great variabil-
ity was revealed in the results for MA-FF vs. Clauss and
FIBTEM (which is a point-of-care method that elimi-
nates the platelet contribution of clot formation by inhi-
biting the platelets irreversibly with cytochalasin D) vs.
Clauss [23].
Our results diverge from those of Harr et al. [19], who
found a close correlation between FLEV and fibrinogen
assayed using the Clauss method in 68 polytrauma pa-
tients (R2 = 0.80). Moreover, Pruller et al. [24] obtained a
fairly good correlation between FLEV and Clauss (R2 =
0.54) in surgical patients. However, conflicting results
have been reported in the literature, depending on the
populations studied; Agarwal et al. [25], for example,
found a weak correlation in cardiac surgical patients
(R2 = 0.11).
Our results show that the two methods are not inter-
changeable because a systematic overestimation obtained
by TEG compared with the Clauss method. In agree-
ment with our data, Katz et al. [26], in 56 parturients,
demonstrated a propensity for the point-of-care method
(FLEV) to overestimate compared with the laboratory
approach (Clauss), especially when the fibrinogen levels
increased above 500 mg/dL (SD 52.8 mg/dL). Agren et
al. [18] obtained similar results, with an overestimation
obtained by FLEV of about 100 mg/dL compared with
the Clauss method. The degree of overestimation de-
tected in the present study was even greater, especially
in pregnant patients with hemorrhage for whom greater
Table 1 Characteristics of the studied population. Values are expressed as median and, in brackets, the interquartile values
Healthy volunteers (n = 32) Non-pathological Pregnant Pts (n = 34) Hemorrhagic Pregnant Pts (n = 32)
Age, years 37 (26–40) 34.5 (31–38) 37.5 (32–40)
Height, cm 167 (163–170.3) 165 (160–168) 167 (163–170.3)
Weight, Kg 75.5 (69.5–87.3) 70.5 (64–80.8) 75.5 (69.5–87.3)
BMI 26.9 (24.2–29.3) 27.2 (25–28.2) 26.9 (24.2–29.3)
Gestational age, weeks + days 36 + 5 (35–37 + 5) 39 (38 + 3–39) 36 + 3 (35 + 4–37 + 2)
Table 2 Studied variables. Values are expressed as median and, in brackets, the interquartile values
Healthy volunteers (n = 32) Non-pathological Pregnant Pts (n = 34) Hemorrhagic Pregnant Pts (n = 32)
FBN Clauss, mg/dL 257.4 (241.4–294.1) 489.8 (437.5–524) 365.5 (307.7–416.5)
FLEV, mg/dL 386.9 (351.8–448.5) 525.6 (490.5–589) 521.9 (483.6–565.7)
MA TEG, mm 55.3 (50.8–60.3) 70.3 (68.3–73) 71.4 (67.1–74.6)
MA FLEV, mm 21.2 (19.3–24.6) 28.8 (26.9–32.3) 28.6 (26.5–31)
PLT, 10^3/μL 237.4 (202.6–263.1) 183.5 (160.9–218.1) 161.7 (132.3–181.5)
Hb, g/dL 13.1 (12.4–13.6) 11.8 (11.4–12.4) 10 (9.2–10.5)
Spasiano et al. BMC Anesthesiology           (2019) 19:90 Page 4 of 8
accuracy is essential – especially since the comparison of
fibrinogen levels between healthy pregnant and pregnant
patients with hemorrhage revealed no statistical differ-
ence for FLEV, whereas the difference did achieve statis-
tical significance with the Clauss method, which could
distinguish the two populations based on fibrinogen
levels. Once again, we must highlight the possibility that
an overestimation of fibrinogen level by FLEV could
cause a delay in treatment in clinical practice.
What underlies the difference between the two tests?
First of all, Clauss is a quantitative method, whereas
FLEV is qualitative. Second, FLEV measures the fibrino-
gen in whole blood, whereas the Clauss method uses
plasma [27]. Third, the non-concordance between FLEV
and the Clauss method is probably due to the impossi-
bility of obtaining a complete inhibition of platelets in
whole blood samples. The lyophilized tissue factor and
the abciximab that binds to glycoprotein IIb/IIIa
Fig. 1 Bland-Altman charts for each group considered (healthy volunteers, ie "Healthy", non pathological pregnant patients, ie "Preg", and
hemorrhagic pregnant patients, ie "Hemorr Preg"). On the y-axis the differences are set, the measured fibrinogen values are placed on the x-axis
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receptors inhibit platelet aggregation and exclude the
contribution of platelets to clot strength. However, Lang
et al. demonstrated [28] that abciximab does not inacti-
vate the glycoproteins completely. Furthermore, when
the number of platelets increases, a smaller percentage
is inhibited and the inaccuracy of the FLEV value in-
creases. Fluid management during anesthesia may also
play a role [29, 30]. Last, but not least, hematocrit and
activated factor XIII could have an impact on clot firm-
ness and affect the correlation [31, 32]. As discussed
above, we recommend continuation of the Clauss la-
boratory reference method; hospital staff should en-
deavor to shorten the delivery time of blood samples to
the laboratory and to speed up subsequent processing
times through, for example, utilization of a priority
channel.
Limitations
The FLEV and the Clauss values are expressed as analyt-
ical variables. We conducted frequent quality controls;
double assays of analyzed samples were often performed
to minimize the pre-analytical error, and the values set
as the laboratory reference range are obtained from the
average of a large pool of healthy volunteers. The major
limitation of the FLEV method is the incomplete inhib-
ition of platelets with the current reagent.
Conclusions
At present, FLEV should not be considered an inter-
changeable alternative to the Clauss method, especially
when dealing with pregnant term women and
hemorrhagic pregnant patients because it overestimates
the fibrinogen level in the blood. As such, it should not
be used in the treatment of hemorrhagic patients with
hypofibrinogenemia. Therefore, at present, it is reason-
able to use the Clauss method by constructing a specific
protocol with an emergency channel to shorten sample
analysis times and guarantee the timely correction of
hypofibrinogenemia.
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